Form 4: Hinge Health 10% Owner and Director Sells Over 1.3 Million Shares Following Conversion

11.2 Capital I Partners, LLC, a 10% owner and director of Hinge Health, Inc., reported the sale of 1,396,340 shares of Class A Common Stock for $32.00 per share, following the conversion of an equivalent number of Class B Common Stock shares.

Summary

• 11.2 Capital I Partners, LLC, along with related entities and Shelley Zhuang, identified as a Director and 10% Owner of Hinge Health, Inc. (HNGE), reported transactions on May 23, 2025.
• The reporting persons converted 1,396,340 shares of Class B Common Stock into Class A Common Stock.
• Immediately following the conversion, 1,396,340 shares of Class A Common Stock were sold at a price of $32.00 per share.
• Prior to these transactions, various series of preferred stock (S-1, A-1, A-2, C, D) totaling 5,100,864 shares were reclassified and converted into Class B Common Stock, as per the Issuer's initial public offering terms.
• After the reported transactions, the reporting persons beneficially own a total of 3,704,524 shares of Class B Common Stock indirectly through 11.2 Capital I (2,703,954 shares), 11.2 Capital HH, LLC (171,550 shares), and 11.2 Capital IVY (829,020 shares).

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to a significant insider sale, which can be perceived as a lack of confidence. However, the fact that it was executed under a 10b5-1 plan mitigates some of the negative impact, suggesting a pre-planned liquidation rather than a reaction to adverse news.

Positives

• The sale was made pursuant to a Rule 10b5-1(c) pre-arranged trading plan, indicating a structured and pre-determined liquidation strategy rather than an immediate reaction to new information, which can reduce market uncertainty.
• The transaction demonstrates liquidity for early investors, which can be a positive signal for future investment in the company.

Negatives

• A significant sale of 1,396,340 shares by a 10% owner and director, even if pre-planned, can be perceived negatively by the market as it reduces insider ownership and may signal a lack of further upside potential from the insider's perspective.
• The sale price of $32.00 per share sets a recent benchmark for a large block trade, which could influence short-term market sentiment.

Risks

• The reduction in beneficial ownership by a significant institutional investor and director could be interpreted by the market as a decrease in confidence, potentially leading to downward pressure on the stock price.
• Future sales by the remaining Class B Common Stock holders (3,704,524 shares) could introduce further supply into the market, potentially impacting share price.

Future Outlook

This Form 4 filing does not provide any forward-looking statements or guidance regarding the company's future financial performance or strategic direction. It solely reports changes in beneficial ownership.

Industry Context

This filing is a standard disclosure of insider trading activity. It does not provide direct insights into broader industry trends or competitive landscape, but rather reflects a specific investor's portfolio management decisions within the digital health sector.

Related Party Transactions

• The sale of Class A Common Stock by 11.2 Capital I Partners, LLC and its related entities, which are 10% owners and have a director on the board of Hinge Health, Inc., constitutes a related party transaction.

Stakeholder Impact

• Shareholders: May react to the significant insider sale, potentially influencing short-term stock price movements and investor sentiment.
• Employees: No direct impact mentioned, but general market sentiment can indirectly affect employee morale and stock-based compensation value.

Key Dates

Keywords

Hinge Health, HNGE, Form 4, insider trading, beneficial ownership, stock sale, 10% owner, director, equity conversion, 10b5-1 plan